Guardant Health’s Post

Transformation in action...

Over the past year, we’ve had the privilege of demonstrating “what’s possible” for the future of cancer treatment to the global oncology community. Daiichi Sankyo’s clinical research from across our oncology portfolio was featured in presidential symposiums, as well as late breaking oral and poster presentations on some of the world’s most significant stages for sharing oncology research including: ✔ American Society of Clinical Oncology (#ASCO23) ✔ European Hematology Association (#EHA23) ✔ International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer (#WCLC23) ✔ ESMO – European Society for Medical Oncology (#ESMO23) ✔ The San Antonio Breast Cancer Symposium (#SABCS23) ✔ The American Society of Hematology (#ASH23) If you’re interested in learning about the clinical research across our #oncology portfolio that’s been shared throughout 2023, our annual R&D Day content is now available on demand. You can also view recent data highlights from #SABCS23 and #ASH23 that span multiple types of solid and blood cancers. Click the link to hear from our R&D leaders as they share Daiichi Sankyo’s latest clinical research and global R&D strategy updates. https://bit.ly/3Ni3ZXx You can also learn more about the individual people behind our global R&D in Our Stories here: https://bit.ly/3uYkPEf

Some major changes for systemic therapies in the updated National Comprehensive Cancer Network® (NCCN®) guidelines are in - Toni Choueiri KidneyCAN Kidney Cancer Association Dana-Farber Lank Center for Genitourinary Oncology Wenxin (Vincent) Xu #Cancer #CancerTreatment #NCCNGuidelines #RCC #OncoDaily #Oncology #RenalCell #Carcinoma

𝐀𝐈 𝐓𝐨𝐨𝐥 𝐢𝐬 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐨𝐟 𝐇𝐄𝐑2 PathAI has announced the launch of AIM-HER2 Breast Cancer, its AI-enabled HER2 scoring algorithm for research use by clinical laboratories, researchers, and drug developers. PathAI's pioneering AIM-HER2, an AI-powered HER2 scoring algorithm, not only signifies a major leap in oncology but also a landmark moment for AI as a whole. 1️⃣ Achieving a remarkable 94.5% agreement with expert pathologists in over 3,800 cases, it guarantees improved accuracy in breast cancer diagnosis, particularly for the 20% of patients who are HER2-positive.  2️⃣ Its potential to reduce the current 14-20% global inaccuracy in HER2 test results showcases how far we've come in our fight against breast cancer. Furthermore, AIM-HER2 is poised to become a powerful tool in cancer research, aiding us in better understanding this challenging disease and developing new treatment strategies. Looking forward to examining the initial results and awaiting the next significant milestone - full registration, I'm confident it's just around the corner 🔬 Full article: https://lnkd.in/dNvUyzTw

A forum to discuss the most recent developments in oncology care: 8th Cancer World Congress 2024, Dubrovnik, Croatia https://lnkd.in/gRG9ZZWb #cancer #breastcancer #lungcancer #cancerresearch #cancerconference #cwc2024 #cancerawareness #cancercare #cancersupport #cancerprevention #CancerWorldCongress #earlybirdregistration #OncoDaily #Croatia #CancerResearch #CancerDiagnostics #CancersMDPI #MDPI #CancerNews #oncology #cancerconferences #oncologyconference #cwc2024 #prostatecancer #croatia #lungcancer #cancergenetics #coloncancer #prostatecancer #skincancer #pancreaticcancer #thyroidcancer #oralcancer #cancerworldcongress #cancerconference2024 #Oncologysymposiums #oncologymeetings #Cancerseminars #Cancertherapyevents #conferences #earlybird

Daiichi Sankyo poured intensive effort into building a high-potential oncology portfolio based on our proprietary DXd #ADC Technology, which is already changing the standard of care for today’s patients. Now that we are starting to realize the promise of our medicines, our pipeline (spanning multiple tumor types), continues to serve as the driving force propelling our company forward in oncology. This past week we held our annual R&D Day where our recent clinical milestones, the trajectory of our pipeline, and Daiichi Sankyo’s global R&D strategy were on full display. With our first 5 DXd ADCs we seek to expand on our leadership in breast cancer to deliver additional treatment options. These options have the potential to improve patient outcomes for a broad set of distinct patient segments and to deliver practice-changing medicines to meet evolving unmet needs in lung cancer for a broad set of distinct patient types. We also seek to build upon the success of our DXd ADC platform and harness the potential of our full oncology portfolio to extend our medicines to more patients, including gynecological, genitourinary, and gastro-intestinal cancers. I encourage those in my #LinkedIn network who are eager to learn more of how we plan to further transform the oncology treatment landscape by expanding our medicines into new tumor types and patient populations, to download our on-demand material. https://bit.ly/3Ni3ZXx As we reflect on the above and all the work of this past year, we must also recognize how much unmet need still exists in oncology, and work with urgency to craft the foundations for even more breakthroughs in 2024 and beyond.

The best treatment for most patients is a well designed clinical trial!

📢 An important message from Neuroendocrine Cancer UK! It is critical to have the #patient voice when developing and designing #clinicaltrials. Patients help to make sure we're researching things that matter and that we're designing trials that are accessible and impactful. #clinicalresearch #oncology #cancerresearch

🔬 Exciting News in Oncology Research! 🔬 At Lampgen Clinical Research, we are always on the lookout for groundbreaking advancements in cancer therapy that could potentially reshape clinical trial landscapes. A recent phase 1 trial led by Mustang Bio and City of Hope has shown promising results in treating recurrent glioblastoma with CAR-T therapy. This study, the largest of its kind for glioblastoma, demonstrated stable disease or better in half of the subjects, with one patient remaining cancer-free for over five years! This trial is particularly notable for its innovative approach of injecting CAR-T cells directly into the brain tumor and cerebrospinal fluid. This method could revolutionize treatment strategies for this aggressive form of brain cancer. We are thrilled about the potential this holds for future clinical trials and the patients they serve. As a staffing firm specializing in oncology clinical research associates, Lampgen is proud to support trials that push the boundaries of current cancer treatments. We believe that with the right team and expertise, anything is possible in the fight against cancer. #OncologyResearch #ClinicalTrials #CARTherapy #Glioblastoma #CancerResearch #InnovationInCancer #ClinicalResearchAssociates #LampgenClinicalResearch #HopeInResearch #FightCancer #MedicalAdvancements

AACI published findings from the 2023 CRI survey of Cancer Clinical Trial offices in ASCO journal JCO Oncology Practice in July 2024. The article titled "North American Cancer Center Clinical Research Capacity and Benchmarking in the Post-Pandemic Era" concludes contemporary benchmarks for CTO operations demonstrating larger staff sizes, larger budgets, more trials supported but fewer patients enrolled to interventional treatment trials compared to 2018. While we are aware of the increasing complexity of cancer clinical trials, the results draw attention to the importance of external funding sources for CTO operations and the imminent need to address operational efficiency. https://lnkd.in/gz5Ny97D